Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Molina-Cerrillo

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Archivos Espanoles De Urologia|June 16, 2020
Renal cell carcinoma and COVID-19 pandemia: Management strategies adapted to current practiceVital Hevia, Estefanía Linares-Espinós, Teresa Alonso-Gordoa, et al.
European Urology Focus|February 23, 2022
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase InhibitorsMatteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Cancers|March 14, 2019
Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAsElisa Conde Moreno, Alejandro Pascual, Daniel Prieto-Cuadra, et al.
Clinical Genitourinary Cancer|March 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World ComparisonMatteo Santoni, Gaetano Aurilio, Francesco Massari, et al.
Translational Lung Cancer Research|August 12, 2022
Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case reportJavier Pozas, Víctor Albarrán-Fernández, Luis González-Campo, et al.
Biochemistry and Biophysics Reports|August 18, 2025
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)Cristina Aguzzi, Simona De Summa, Javier Molina-Cerrillo, et al.
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
The Oncologist|February 12, 2020
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)Enrique Grande, Alex Teulé, Teresa Alonso-Gordoa, et al.
Targeted Oncology|August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World StudyMatteo Santoni, Francesco Massari, Enrique Grande, et al.
Expert Opinion on Pharmacotherapy|February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working groupConcetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Archivos Espanoles De Urologia|June 16, 2020
Renal cell carcinoma and COVID-19 pandemia: Management strategies adapted to current practiceVital Hevia, Estefanía Linares-Espinós, Teresa Alonso-Gordoa, et al.
European Urology Focus|February 23, 2022
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase InhibitorsMatteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Cancers|March 14, 2019
Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAsElisa Conde Moreno, Alejandro Pascual, Daniel Prieto-Cuadra, et al.
Clinical Genitourinary Cancer|March 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World ComparisonMatteo Santoni, Gaetano Aurilio, Francesco Massari, et al.
Translational Lung Cancer Research|August 12, 2022
Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case reportJavier Pozas, Víctor Albarrán-Fernández, Luis González-Campo, et al.
Biochemistry and Biophysics Reports|August 18, 2025
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)Cristina Aguzzi, Simona De Summa, Javier Molina-Cerrillo, et al.
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
The Oncologist|February 12, 2020
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)Enrique Grande, Alex Teulé, Teresa Alonso-Gordoa, et al.
Targeted Oncology|August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World StudyMatteo Santoni, Francesco Massari, Enrique Grande, et al.
Expert Opinion on Pharmacotherapy|February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working groupConcetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Pageof 10